CGTLive®’s Weekly Rewind – February 14, 2025

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Phase 2 Trial for BMS's Liso-Cel Meets Primary End Point in R/R Marginal Zone Lymphoma Cohort

Liso-cel showed a statistically significant and clinically meaningful overall response rate in the cohort.

2. Reena Sharma, MD, on Assessing Spur Therapeutics’ Gene Therapy FLT201 in Gaucher Disease

The adult metabolic consultant at Salford Royal Hospital discussed results she presented at the 21st Annual WORLDSymposium.

3. No Significant Reduction of CRS or ICANS Seen With Sobi's Anakinra in Patient's Receiving Liso-Cel for LBCL

The data, which comes from a phase 2 trial, were presented at the 2025 Tandem Meetings.

4. CareDx’s AlloHeme Shows Accuracy in Detecting Relapse Following AlloHSCT in AML and MDS

AlloHeme utilizes detection of increased mixed chimerism (iMC) at a threshold of 0.2% or greater in the recipient’s chimerism between 2 consecutive readings to predict relapse.

5. International Epilepsy Day 2025: Looking Back at Progress for Cell and Gene Therapy

In observance of International Epilepsy Day, held annually on the second Monday of February, we took a look back at the past year's news in cell and gene therapy for epilepsy indications.